Results 221 to 230 of about 23,536 (264)

Structural optimization of pyridine-type DAPY derivatives to exploit the tolerant regions of the NNRTI binding pocket.

European journal of medicinal chemistry, 2016
Wenmin Chen, Peng Zhan, D. Daelemans, Jiapei Yang, Bo-Shi Huang, E. De Clercq, C. Pannecouque, Xin-Yong Liu   +7 more
semanticscholar   +1 more source

Next generation NNRTI potent against NNRTI-resistant HIV-1

Inpharma Weekly, 2005
openaire   +1 more source

Minority resistant HIV-1 variants and the response to first-line NNRTI therapy.

Journal of Clinical Virology, 2015
F. Nicot, K. Sauné, S. Raymond, N. Jeanne, R. Carcenac, C. Lefebvre, L. Cuzin, B. Marchou, P. Delobel, J. Izopet   +9 more
semanticscholar   +1 more source

NNRTI-related or -unrelated hepatotoxicity?

Hepatology, 2002
Pascal, Lebray, Yves, Benhamou, Stanislas, Pol, Robert P, Myers, Thierry, Poynard, Vincent, Di Martino   +5 more
openaire   +2 more sources

Exploiting the tolerant region I of the non-nucleoside reverse transcriptase inhibitor (NNRTI) binding pocket. Part 2: Discovery of diarylpyrimidine derivatives as potent HIV-1 NNRTIs with high Fsp values and favorable drug-like properties

European Journal of Medicinal Chemistry, 2021
Zhao Wang, Xiangyi Jiang, Dongwei Kang
exaly  

NNRTI-based antiretroviral therapy may increase risk of radiation induced side effects in HIV-1-infected patients.

Radiotherapy and Oncology, 2015
Keller Ulrike, Hecht Markus, Harrer Thomas, Harrer Ellen, S. Barbara, Fietkau Rainer, L. Distel   +6 more
semanticscholar   +1 more source

Design, synthesis, and evaluation of “dual-site”-binding diarylpyrimidines targeting both NNIBP and the NNRTI adjacent site of the HIV-1 reverse transcriptase

European Journal of Medicinal Chemistry, 2021
Chin-Ho Chen, Xiaofang Zuo, Dongwei Kang
exaly  

NNRTIs: challenges and opportunities

Inpharma Weekly, 2002
openaire   +1 more source

A Novel NNRTI Class with Potent Anti-HIV Activity Against NNRTI-resistant Viruses

Antiviral Research, 2008
Anneke Raney, Robert Hamatake, Wen Xu, Jean-Luc Girardet, Jean-Michel Vernier, Li-Tain Yeh, Barry Quart   +6 more
openaire   +1 more source

Switching to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus continuation of non-nucleoside reverse transcriptase inhibitor with emtricitabine and tenofovir in virologically suppressed adults with HIV (STRATEGY-NNRTI): 48 week results of a randomised, open-label, phase 3b

Lancet. Infectious Diseases (Print), 2014
A. Pozniak, M. Markowitz, A. Mills, H. Stellbrink, A. Antela, P. Domingo, P. Girard, K. Henry, Thai Nguyen, D. Piontkowsky, W. Garner, K. White, Bill Guyer   +12 more
semanticscholar   +1 more source